ClinicalTrials.gov Search

Search for specific clinical trials that are underway using the keyword search below.

Keywords:

Patient support groups also offer information about clinical trials.

Content Provided By

NINDS Disorders is an index of neurological conditions provided by the National Institute of Neurological Disorders and Stroke. This valuable tool offers detailed descriptions, facts on treatment and prognosis, and patient organization contact information for over 500 identified neurological disorders.

  Print-friendly Version

Sydenham Chorea

Sydenham chorea (SD) is a neurological disorder of childhood resulting from infection via Group A beta-hemolytic streptococcus (GABHS), the bacterium that causes rheumatic fever.  SD is characterized by rapid, irregular, and aimless involuntary movements of the arms and legs, trunk, and facial muscles.  It affects girls more often than boys and typically occurs between 5 and 15 years of age. Some children will have a sore throat several weeks before the symptoms begin, but the disorder can also strike up to 6 months after the fever or infection has cleared.  Symptoms can appear gradually or all at once, and also may include uncoordinated movements, muscular weakness, stumbling and falling, slurred speech, difficulty concentrating and writing, and emotional instability.  The symptoms of SD can vary from a halting gait and slight grimacing to involuntary movements that are frequent and severe enough to be incapacitating.  The random, writhing movements of chorea are caused by an auto-immune reaction to the bacterium that interferes with the normal function of a part of the brain (the basal ganglia) that controls motor movements.  Due to better sanitary conditions and the use of antibiotics to treat streptococcal infections, rheumatic fever, and consequently SD, are rare in North America and Europe.  The disease can still be found in developing nations. 

Treatment

There is no specific treatment for SD.  For people with the mildest form, bed rest during the period of active movements is sufficient.  When the severity of movements interferes with rest, sedative drugs, such as barbiturates or benzodiazepines, may be needed.  Antiepileptic medications, such as valproic acid, are often prescribed.  Doctors also recommend that children who have had SD take penicillin over the course of the next 10 years to prevent additional manifestations of rheumatic fever. 

Prognosis

Most children recover completely from SD, although a small number will continue to have disabling, persistent chorea despite treatment.   The duration of symptoms varies, generally from 3 to 6 weeks, but some children will have symptoms for several months.  Cardiac complications may occur in a small minority of children, usually in the form of endocarditis.  In a third of the children with the disease, SD will recur, typically 1 ½ to 2 ½ years after the initial attack.  Researchers have noted an association between recurrent SD and the later development of the abrupt onset forms of obsessive-compulsive disorder, attention deficit/hyperactivity disorder, tic disorders, and autism, which they call PANDAS, for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus infection.  Further studies are needed to determine the nature of the association and the biological pathways that connect streptococcal infection, autoimmune response, and the later development of these specific behavioral disorders.

Research

The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health (NIH) conduct research related to SD in laboratories at the NIH, and support additional research through grants to major medical institutions across the country.  Currently, researchers are studying how the interplay of genetic, developmental, and environmental factors could determine a child’s vulnerability to SD after a GABHS infection.  Other researchers are exploring whether children whose symptoms either begin or get worse following a GABHS infection share a common set of abnormal biomolecular pathways responsible for their similar clinical symptoms. 

View a list of studies currently seeking patients.

View more studies on this condition.

Organizations

National Organization for Rare Disorders (NORD)

Federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. Committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service.

55 Kenosia Avenue
Danbury, CT 06810
Tel: 203-744-0100 Voice Mail 800-999-NORD (6673)
Fax: 203-798-2291

<< Back